演讲者
 The Renaissance in Pharma Fixed Combinations: Where Are We Heading Next?
John Ansell, President, John Ansell Consultancy
 Extending the Life of Blockbuster Products with Innovative Drug Combinations
John Maki, President and Chief Executive Officer, Vicus Therapeutics
 War Stories: Combining a Drug and Device in the Development of Inhalation Products
John S. Patton, Ph.D., Co-Founder and former Chief Research Fellow, Nektar Therapeutics; Founder and President, Dance Pharmaceuticals
 Contemporary and Global Perspectives on Combo Product Lifecycle Management
Makarand S. Jawadekar, Ph.D., Director, Portfolio Management and Performance, Pfizer
 Key Success Factors for Combination Products (patents; approvals; pricing and reimbursement; physician and patient acceptance)
Anthony (Tony) Ellery, Ph.D., former Global Head, Mature Products and Lifecycle Management, Novartis; CEO, ellery pharma consulting
 P&T Committee Perspective: Economic and Therapeutic Imperatives for Fixed-Dose Combination Products and Combination Therapy
Dean G. Smith, Ph.D., Professor and Senior Associate Dean, Health Management & Policy, School of Public Health, University of Michigan
 Regulatory Strategy for Combination Products
Chitkala Kalidas, Director. Worldwide Regulatory Affairs, Merck & Co.
 FDA Regulatory Requirements: UpDate from the FDA Office of Combination Products
Bradley Merrill Thompson, Shareholder, Health Care and Life Sciences Practice, Epstein, Becker & Green, P.C.; General Counsel to the Combination Products Coalition
|
